Tenecteplase vs Alteplase for Acute Ischemic Stroke: What the Evidence Shows
Synthesising data from 11 RCTs involving over 7,500 patients and recent meta-analyses comparing tenecteplase 0.25 mg/kg single bolus to alteplase 0.9 mg/kg infusion for acute ischemic stroke thrombolysis. Evidence through 2025.
This is an original evidence synthesis. See References for source studies.
One-Minute Takeaway
One-Minute Takeaway
- Tenecteplase vs alteplase for acute ischemic stroke has been evaluated in five recent phase 3 RCTs (AcT, TRACE-2, TASTE, ATTEST-2, ORIGINAL), all of which established non-inferiority of tenecteplase 0.25 mg/kg to alteplase 0.9 mg/kg for 90-day functional outcomes within the 4.5-hour treatment window.
- A 2025 meta-analysis of 11 RCTs (7,546 patients at the 0.25 mg/kg dose) found tenecteplase was associated with significantly higher rates of excellent outcome (mRS 0–1) compared with alteplase (OR 1.14, 95% CI 1.03–1.25), with comparable rates of symptomatic intracranial haemorrhage and mortality.
- The 0.4 mg/kg dose of tenecteplase was associated with excess haemorrhage risk and worse outcomes in NOR-TEST 2A and has been definitively abandoned; only the 0.25 mg/kg dose is supported by current evidence.
- Single-bolus administration of tenecteplase offers major logistical advantages over alteplase’s 60-minute infusion, including reduced door-to-needle times, simplified inter-hospital transfer workflows, and lower resource requirements — benefits that may further widen access to thrombolysis.
- ESO guidelines now recommend tenecteplase 0.25 mg/kg as an alternative to alteplase, and emerging consensus favours it as the preferred thrombolytic for acute stroke; however, formal regulatory approval for the stroke indication remains pending in most jurisdictions.
Why This Topic Matters
Intravenous thrombolysis with alteplase has been the cornerstone of acute ischemic stroke treatment for nearly three decades. Despite its proven efficacy, alteplase carries significant practical limitations: it requires weight-based dosing with a 10% bolus followed by a 60-minute infusion, necessitating infusion pumps, continuous monitoring, and ICU-level nursing. These logistical demands contribute to treatment delays, complicate inter-hospital transfers, and limit access in under-resourced settings.
Tenecteplase — a genetically engineered variant of alteplase with 14-fold greater fibrin specificity and an approximately 20-minute half-life (compared to 4–5 minutes for alteplase) — can be administered as a single intravenous bolus over 5–10 seconds. This simplification has the potential to transform stroke care logistics, particularly in drip-and-ship models where patients are thrombolysed at a primary centre before transfer for thrombectomy.
An accelerating series of phase 3 trials has now addressed the key clinical question: does this logistical advantage come without sacrificing efficacy or safety? This synthesis examines the totality of that evidence.
What Evidence Was Reviewed
This synthesis draws on five recent phase 3 non-inferiority RCTs, earlier phase 2 and phase 3 studies, and multiple systematic reviews and meta-analyses. Only studies comparing tenecteplase 0.25 mg/kg to alteplase 0.9 mg/kg within the standard 4.5-hour window are included in the primary analysis, given that the 0.4 mg/kg dose has been conclusively shown to carry excess risk.
| Study | Design | n | Population | Key Finding | Quality |
|---|---|---|---|---|---|
| AcT (Menon et al. 2022) | Phase 3 NI RCT | 1577 | AIS ≤4.5 h, Canada, pragmatic | mRS 0–1: 36.9% vs 34.8% (RD 2.1%, 95% CI −2.6 to 6.9); non-inferiority met | High |
| TRACE-2 (Wang et al. 2023) | Phase 3 NI RCT | 1430 | AIS ≤4.5 h, China, no EVT | mRS 0–1: 62.7% vs 56.6% (RD 6.0%, 95% CI 1.5–10.6); non-inferiority and superiority met | High |
| TASTE (Parsons et al. 2024) | Phase 3 NI RCT | 577 | AIS ≤4.5 h, perfusion-imaging selected, Australia/Singapore | mRS 0–1: 69.3% vs 68.2% (RD 0.7%, 95% CI −6.7 to 8.2); non-inferiority met | High |
| ATTEST-2 (Muir et al. 2024) | Phase 3 NI RCT | 539 | AIS ≤4.5 h, UK, 39 centres | mRS 0–1: 51.0% vs 50.0% (aOR 1.07, 95% CI 0.77–1.48); non-inferiority met | High |
| ORIGINAL (Meng et al. 2024) | Phase 3 NI RCT | 1816 | AIS ≤4.5 h, China | mRS 0–1: 66.4% vs 64.0% (RD 2.4%, 95% CI −1.4 to 6.2); non-inferiority met | High |
| NOR-TEST (Logallo et al. 2017) | Phase 3 RCT | 1100 | AIS ≤4.5 h, Norway (0.4 mg/kg) | mRS 0–1: 64% vs 63%; non-significant (high rate of mild stroke/mimics) | Moderate |
| NOR-TEST 2A (Kvistad et al. 2022) | Phase 3 NI RCT | 204 | AIS ≤4.5 h, NIHSS ≥6, Norway (0.4 mg/kg) | Stopped early for safety; mRS 0–1: 32% vs 51% (OR 0.45); excess ICH with 0.4 mg/kg | High |
| EXTEND-IA TNK (Campbell et al. 2018) | Phase 2 RCT | 202 | LVO, pre-thrombectomy | Greater reperfusion with tenecteplase 0.25 mg/kg vs alteplase before EVT | Moderate |
| Palaiodimou et al. 2024 | SR & MA (8 RCTs) | 3598 | TNK 0.25 mg/kg vs alteplase ≤4.5 h | mRS 0–1 favoured tenecteplase (OR 1.14); comparable sICH; TSA boundary crossed | High |
| Sheraz et al. 2025 | SR & MA (11 RCTs) | 7546 | TNK 0.25 mg/kg vs alteplase | Excellent outcome significantly favoured tenecteplase (OR 1.14, 95% CI 1.03–1.25) | High |
| CERTAIN (Warach et al. 2023) | Prospective observational | 7937 | Real-world US registry comparison | sICH rates comparable: 2.3% (TNK) vs 2.9% (alteplase); similar functional outcomes | Moderate |
Key Findings: Tenecteplase vs Alteplase in Acute Ischemic Stroke
Non-Inferiority Established Across Five Phase 3 Trials
The five recent phase 3 non-inferiority trials — AcT (Canada, n=1577), TRACE-2 (China, n=1430), TASTE (Australia/Singapore, n=577), ATTEST-2 (UK, n=539), and ORIGINAL (China, n=1816) — collectively enrolled over 5,900 patients and uniformly established that tenecteplase 0.25 mg/kg is non-inferior to alteplase 0.9 mg/kg for the primary outcome of excellent functional recovery (mRS 0–1) at 90 days. Rates of mRS 0–1 with tenecteplase ranged from 36.9% to 69.3% across trials (reflecting differences in stroke severity, selection criteria, and baseline NIHSS).
Critically, rates of symptomatic intracranial haemorrhage (sICH) were consistently comparable between agents, ranging from 1.4% to 3.4% with tenecteplase and 1.3% to 3.2% with alteplase across the major trials. Mortality at 90 days was also similar between arms in all five studies. These concordant findings across diverse populations — spanning high-income healthcare systems in Canada, the UK, and Australia, as well as large multicentre trials in China — provide strong evidence for generalisability.
Meta-Analytic Evidence: From Non-Inferiority Toward Superiority
Two recent meta-analyses have synthesised the full body of RCT evidence at the 0.25 mg/kg dose. Palaiodimou and colleagues (Neurology, 2024) pooled eight trials involving 3,598 patients treated within 4.5 hours and found that tenecteplase was associated with higher rates of mRS 0–1 at 90 days (OR 1.14), with comparable sICH rates. Trial sequential analysis indicated that the cumulative evidence had crossed the boundary for establishing non-inferiority and was approaching the threshold for superiority.
An updated 2025 meta-analysis by Sheraz and colleagues, incorporating 11 RCTs with 7,546 patients at the 0.25 mg/kg dose, confirmed a statistically significant improvement in excellent functional outcome with tenecteplase (OR 1.14, 95% CI 1.03–1.25). Rates of sICH, all-cause mortality, and poor functional outcome (mRS 4–6) remained statistically comparable between the two agents. These pooled data provide the strongest evidence to date that tenecteplase 0.25 mg/kg is at least equivalent to — and likely modestly superior to — alteplase for 90-day functional outcomes.
Early trials, particularly NOR-TEST (2017), used tenecteplase at 0.4 mg/kg — the dose extrapolated from myocardial infarction treatment. While NOR-TEST found similar outcomes to alteplase, it enrolled predominantly mild strokes (median NIHSS 4), limiting interpretability. When NOR-TEST 2A subsequently tested 0.4 mg/kg in patients with moderate-to-severe strokes (NIHSS ≥6), the trial was stopped early for safety: intracranial haemorrhage occurred in 21% of tenecteplase-treated patients versus 7% with alteplase, and 3-month mortality was 16% versus 5%.
Concurrently, the EXTEND-IA TNK Part 2 trial found no efficacy advantage of 0.4 mg/kg over 0.25 mg/kg in the pre-thrombectomy setting. Network meta-analyses rank 0.25 mg/kg highest for both efficacy and safety among the thrombolysis regimens evaluated. The 0.4 mg/kg dose is now considered definitively abandoned for stroke, and all current guideline recommendations specify 0.25 mg/kg exclusively.
The initial EXTEND-IA TNK trial (2018) generated considerable enthusiasm by demonstrating greater reperfusion of the target vessel territory with tenecteplase 0.25 mg/kg compared to alteplase before thrombectomy in patients with large vessel occlusion (LVO). However, subsequent larger studies have not replicated this signal. A prespecified secondary analysis of the AcT trial found no significant differences in reperfusion rates, functional outcomes, sICH, or mortality between tenecteplase and alteplase among the 520 patients with LVO.
The TASTE trial, which used perfusion imaging to select patients, similarly did not find differential benefit in the LVO subgroup. Current evidence suggests tenecteplase and alteplase produce equivalent outcomes in LVO stroke, though the logistical advantage of single-bolus tenecteplase in the drip-and-ship workflow remains a strong practical argument for its use in this population.
Beyond clinical equivalence or possible superiority, the practical case for tenecteplase is compelling. Single-bolus administration eliminates the need for infusion pumps, reduces the nursing burden of 60-minute infusion monitoring, and simplifies weight-based dosing calculations. Real-world implementation studies from Australia, New Zealand, and multiple European centres have reported reductions in door-to-needle times of 7–15 minutes, faster door-to-puncture times in patients transferred for thrombectomy, and reduced medication errors.
For drip-and-ship stroke networks — where patients receive thrombolysis at a primary centre before ambulance transfer to a comprehensive stroke centre for potential thrombectomy — the bolus-only approach eliminates the challenge of continuing an alteplase infusion during transport, freeing ambulance staff from infusion management. This logistical simplification is a primary driver behind guideline bodies favouring tenecteplase even in the absence of proven clinical superiority.
Alteplase has established RCT evidence for use in the extended time window (4.5–9 hours) and wake-up stroke based on perfusion imaging selection (EXTEND, ECASS-4 trials). Tenecteplase data in this setting are less mature. The TIMELESS trial (2024) evaluated tenecteplase 0.25 mg/kg in the 4.5–24-hour window with perfusion imaging selection but did not demonstrate significant improvement in disability outcomes at 90 days, though the majority of enrolled patients also received endovascular thrombectomy.
This remains an important evidence gap: while alteplase’s extended-window efficacy is supported by positive RCT data, equivalent evidence for tenecteplase is not yet available. Clinicians should be aware that using tenecteplase beyond 4.5 hours from last known well currently lacks the same level of trial support as alteplase in this setting, though it is being evaluated in ongoing trials.
Real-World Safety Data: The CERTAIN Collaboration
The largest real-world comparative dataset comes from the CERTAIN collaboration (2023), which analysed outcomes in 7,937 patients across US stroke centres that had transitioned from alteplase to tenecteplase. Rates of sICH were comparable at 2.3% with tenecteplase versus 2.9% with alteplase, and functional outcomes were similar. These observational data provide important reassurance that the safety profile observed in the controlled RCT setting translates to routine clinical practice, including in centres with varying levels of stroke expertise.
Quality & Consistency of Evidence
What the Evidence Does Not Show
Extended time window equivalence: Alteplase has positive RCT evidence for imaging-selected patients in the 4.5–9-hour window and wake-up stroke. Equivalent RCT data for tenecteplase in this setting do not yet exist, and the TIMELESS trial was negative. Clinicians using tenecteplase in the extended window currently do so without the same evidence base.
Regulatory approval for stroke indication: Tenecteplase does not have formal regulatory approval for stroke in most countries (including the US, EU, and UK). Its use in stroke is off-label, supported by guidelines and growing institutional adoption. This regulatory gap affects formulary decisions, liability considerations, and insurance coverage.
Cost-effectiveness across healthcare systems: While tenecteplase may reduce downstream costs through simplified workflow and shorter treatment times, formal health-economic analyses incorporating the full range of trial data are limited. Direct drug cost comparisons depend on regional pricing and availability of stroke-specific tenecteplase vial formulations versus cardiac dosing.
Dosing errors with cardiac-dose vials: Tenecteplase is marketed in cardiac-dose vials (typically 50 mg). Using these for the stroke dose (0.25 mg/kg, typically 15–25 mg) requires careful dose calculation and waste. Stroke-specific 25 mg vials are available in some markets but not all, creating a recognised risk of dosing error during the transition period.
Practical Implications
Based on the current evidence, the following considerations may inform decisions about transitioning from alteplase to tenecteplase for acute stroke thrombolysis.
Five concordant phase 3 RCTs and meta-analytic synthesis provide strong evidence for non-inferiority and likely modest superiority of tenecteplase over alteplase in the standard treatment window. ESO guidelines already recommend tenecteplase as an alternative, and expert consensus increasingly favours it as the preferred agent.
Single-bolus administration reduces door-to-needle time, eliminates infusion pump requirements, simplifies inter-hospital transfer, and reduces nursing workload. These logistical advantages may be particularly impactful in drip-and-ship networks and resource-limited settings, potentially expanding access to thrombolysis.
The evidence base for tenecteplase beyond 4.5 hours from last known well is substantially weaker than for alteplase. Clinicians and institutions transitioning to tenecteplase should have clear protocols addressing this gap — either maintaining alteplase availability for extended-window cases or explicitly acknowledging the lower certainty of evidence.
Implementation of tenecteplase for stroke should preferentially use stroke-specific 25 mg vials where available. Institutions using cardiac-dose 50 mg vials should implement robust dosing safeguards, including weight-based dose calculators, pharmacy verification protocols, and staff education to mitigate the risk of inadvertent overdosing.
Evidence Grade & Bottom Line
Evidence Grade: Strong (for ≤4.5 h time window)
Five concordant phase 3 RCTs with over 5,900 patients, supported by meta-analyses exceeding 7,500 patients and large real-world safety data, provide high-certainty evidence that tenecteplase 0.25 mg/kg is non-inferior to alteplase for acute ischemic stroke thrombolysis within 4.5 hours. The evidence is consistent across diverse populations, stroke severities, and healthcare systems.
- Tenecteplase 0.25 mg/kg is non-inferior to alteplase 0.9 mg/kg for 90-day functional outcomes in acute ischemic stroke treated within 4.5 hours, with comparable rates of symptomatic haemorrhage and mortality.
- Meta-analysis of over 7,500 patients suggests a modest but statistically significant improvement in excellent outcomes (mRS 0–1) with tenecteplase (OR 1.14, 95% CI 1.03–1.25).
- Single-bolus administration offers major logistical advantages including reduced door-to-needle times, simplified transfer workflows, and lower resource requirements.
- The 0.4 mg/kg dose is associated with excess haemorrhage and mortality and must not be used for stroke.
- Tenecteplase evidence in the extended time window (4.5–9 h and wake-up stroke) remains limited compared to alteplase, representing the most important remaining evidence gap.
Article Information
For Educational Purposes Only. This is an original evidence synthesis informed by the studies listed below. It does not replace clinical judgement. Drug dosages should be verified against current prescribing information.
References
- Sheraz M, Asif N, Khan A, et al. Tenecteplase versus alteplase in patients with acute ischemic stroke: an updated meta-analysis of randomized controlled trials. J Stroke Cerebrovasc Dis. 2025;34(6):108300. DOI: 10.1016/j.jstrokecerebrovasdis.2025.108300
- Palaiodimou L, Katsanos AH, Turc G, et al. Tenecteplase vs alteplase in acute ischemic stroke within 4.5 hours: a systematic review and meta-analysis of randomized trials. Neurology. 2024;103(9):e209903. DOI: 10.1212/WNL.0000000000209903
- Menon BK, Buck BH, Singh N, et al. Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT). Lancet. 2022;400(10347):161–169. DOI: 10.1016/S0140-6736(22)01054-6
- Wang Y, Li S, Pan Y, et al. Tenecteplase versus alteplase in acute ischaemic cerebrovascular events (TRACE-2). Lancet. 2023;401(10377):645–654. DOI: 10.1016/S0140-6736(22)02600-9
- Parsons MW, Yogendrakumar V, Churilov L, et al. Tenecteplase versus alteplase for thrombolysis in patients selected by use of perfusion imaging (TASTE). Lancet Neurol. 2024;23:775–786. DOI: 10.1016/S1474-4422(24)00206-0
- Muir KW, Ford GA, Ford I, et al. Tenecteplase versus alteplase for acute stroke within 4.5 h of onset (ATTEST-2). Lancet Neurol. 2024;23:1087–1096. DOI: 10.1016/S1474-4422(24)00377-6
- Meng X, Li S, Dai H, et al. Tenecteplase vs alteplase for patients with acute ischemic stroke: the ORIGINAL randomized clinical trial. JAMA. 2024;332:1437–1445. DOI: 10.1001/jama.2024.14721
- Kvistad CE, Næss H, Helleberg BH, et al. Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2, part A). Lancet Neurol. 2022;21(6):511–519. DOI: 10.1016/S1474-4422(22)00124-7
- Campbell BCV, Mitchell PJ, Churilov L, et al. Tenecteplase versus alteplase before thrombectomy for ischemic stroke (EXTEND-IA TNK). N Engl J Med. 2018;378:1573–1582. DOI: 10.1056/NEJMoa1716405
- Warach SJ, Ranta A, Kim J, et al. Symptomatic intracranial hemorrhage with tenecteplase vs alteplase in patients with acute ischemic stroke: the CERTAIN collaboration. JAMA Neurol. 2023;80:732–738. DOI: 10.1001/jamaneurol.2023.1449
- Campbell BCV. Should we switch to tenecteplase for all ischemic strokes? Evidence and logistics. Int J Stroke. 2025;20(3):255–260. DOI: 10.1177/17474930241303089
- Logallo N, Novotny V, Assmus J, et al. Tenecteplase versus alteplase for management of acute ischaemic stroke (NOR-TEST). Lancet Neurol. 2017;16(10):781–788. DOI: 10.1016/S1474-4422(17)30253-3